Drug
Preparative Regimen
Preparative Regimen is a pharmaceutical drug with 5 clinical trials. Historical success rate of 100.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 4 completed trials
Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
75%(3 trials)
Phase Distribution
Ph phase_1
2
40%
Ph phase_2
2
40%
Ph phase_3
1
20%
Phase Distribution
2
Early Stage
2
Mid Stage
1
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
2(40.0%)
Phase 2Efficacy & side effects
2(40.0%)
Phase 3Large-scale testing
1(20.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
4 of 4 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Completed(4)
Other(1)
Detailed Status
Completed4
unknown1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 12 (40.0%)
Phase 22 (40.0%)
Phase 31 (20.0%)
Trials by Status
completed480%
unknown120%
Recent Activity
0 active trials
Showing 5 of 5
completedphase_1
Haploidentical Donor Natural Killer Cell Infusion With IL-15 in Acute Myelogenous Leukemia (AML)
NCT01385423
completedphase_1
Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML)
NCT00167219
unknownphase_3
Personalized Targeted Preparative Regimen Before T-depleted Allogeneic HSCT in Children With Chemoresistent Acute Leukemias
NCT04000698
completedphase_2
NK Cell Based Non-Myeloablative Transplantation in Acute Myeloid Diseases
NCT01370213
completedphase_2
Umbilical Cord Blood Transplantation In Patients With Hematologic Malignancies Using A Myeloablative Preparative Regimen
NCT01328496
Clinical Trials (5)
Showing 5 of 5 trials
NCT01385423Phase 1
Haploidentical Donor Natural Killer Cell Infusion With IL-15 in Acute Myelogenous Leukemia (AML)
NCT00167219Phase 1
Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML)
NCT04000698Phase 3
Personalized Targeted Preparative Regimen Before T-depleted Allogeneic HSCT in Children With Chemoresistent Acute Leukemias
NCT01370213Phase 2
NK Cell Based Non-Myeloablative Transplantation in Acute Myeloid Diseases
NCT01328496Phase 2
Umbilical Cord Blood Transplantation In Patients With Hematologic Malignancies Using A Myeloablative Preparative Regimen
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5